Suppliers / Haupt Pharma Wuelfing

Haupt Pharma Wuelfing

Germany Updated 9 July 2026

Haupt Pharma Wuelfing is a finished-dose manufacturer based in Germany. It appears in 38 regulatory filings across 1 regulator, without an active US DMF or CEP on file. Its GMP standing is certified by ZLG (DE) and US FDA. Its most recent recorded inspection, by US FDA, closed on 6 June 2023 as VAI.

0
active US DMFs
0
valid CEPs
2
registered plants 1 with an FDA FEI number
38
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
6 of 6 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 6 June 2023 VAI US FDA
  • 7 December 2018 NAI US FDA
  • 17 March 2017 NAI US FDA
  • 28 March 2014 VAI US FDA
  • 20 April 2012 VAI US FDA
  • 6 November 2008 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Gronau/Leine, Germany Not on file
Germany, Germany 3003183252

Filings and GMP by regulator

Regulator Filings GMP certificates
NPRA (MY) 38 None
ZLG (DE) None 2
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Haupt Pharma Wuelfing comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 6 June 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates